321 related articles for article (PubMed ID: 25533646)
1. Randomised controlled trial of mesalazine in IBS.
Barbara G; Cremon C; Annese V; Basilisco G; Bazzoli F; Bellini M; Benedetti A; Benini L; Bossa F; Buldrini P; Cicala M; Cuomo R; Germanà B; Molteni P; Neri M; Rodi M; Saggioro A; Scribano ML; Vecchi M; Zoli G; Corinaldesi R; Stanghellini V
Gut; 2016 Jan; 65(1):82-90. PubMed ID: 25533646
[TBL] [Abstract][Full Text] [Related]
2. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).
Lam C; Tan W; Leighton M; Hastings M; Lingaya M; Falcone Y; Zhou X; Xu L; Whorwell P; Walls AF; Zaitoun A; Montgomery A; Spiller R
Gut; 2016 Jan; 65(1):91-9. PubMed ID: 25765462
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.
Leighton MP; Lam C; Mehta S; Spiller RC
Trials; 2013 Jan; 14():10. PubMed ID: 23302220
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity.
Castro Tejera V; Öhman L; Aabakken L; Fellström B; Hausken T; Hovde Ø; Hreinsson JP; Lindberg G; Venge P; Simrén M; Törnblom H
Aliment Pharmacol Ther; 2022 Sep; 56(6):968-979. PubMed ID: 35942522
[TBL] [Abstract][Full Text] [Related]
5. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon--a placebo-controlled study.
Kruis W; Meier E; Schumacher M; Mickisch O; Greinwald R; Mueller R;
Aliment Pharmacol Ther; 2013 Apr; 37(7):680-90. PubMed ID: 23414061
[TBL] [Abstract][Full Text] [Related]
6. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J
Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234
[TBL] [Abstract][Full Text] [Related]
7. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM
Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
[TBL] [Abstract][Full Text] [Related]
8. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
[TBL] [Abstract][Full Text] [Related]
9. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome.
Andrews CN; Griffiths TA; Kaufman J; Vergnolle N; Surette MG; Rioux KP
Aliment Pharmacol Ther; 2011 Aug; 34(3):374-83. PubMed ID: 21671966
[TBL] [Abstract][Full Text] [Related]
10. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
Weerts ZZRM; Masclee AAM; Witteman BJM; Clemens CHM; Winkens B; Brouwers JRBJ; Frijlink HW; Muris JWM; De Wit NJ; Essers BAB; Tack J; Snijkers JTW; Bours AMH; de Ruiter-van der Ploeg AS; Jonkers DMAE; Keszthelyi D
Gastroenterology; 2020 Jan; 158(1):123-136. PubMed ID: 31470006
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of mesalazine to treat irritable bowel syndrome: A meta-analysis.
Zhang FM; Li S; Ding L; Xiang SH; Zhu HT; Yu JH; Xu GQ
Medicine (Baltimore); 2019 Jul; 98(28):e16297. PubMed ID: 31305414
[TBL] [Abstract][Full Text] [Related]
13. Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine.
Bafutto M; Almeida JR; Leite NV; Oliveira EC; Gabriel-Neto S; Rezende-Filho J
Arq Gastroenterol; 2011; 48(1):36-40. PubMed ID: 21537540
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
[TBL] [Abstract][Full Text] [Related]
15. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study.
Corinaldesi R; Stanghellini V; Cremon C; Gargano L; Cogliandro RF; De Giorgio R; Bartesaghi G; Canovi B; Barbara G
Aliment Pharmacol Ther; 2009 Aug; 30(3):245-52. PubMed ID: 19438846
[TBL] [Abstract][Full Text] [Related]
16. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.
Tack JF; Miner PB; Fischer L; Harris MS
Aliment Pharmacol Ther; 2011 Oct; 34(8):868-77. PubMed ID: 21883322
[TBL] [Abstract][Full Text] [Related]
17. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
18. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study.
Tursi A; Brandimarte G; Elisei W; Picchio M; Forti G; Pianese G; Rodino S; D'Amico T; Sacca N; Portincasa P; Capezzuto E; Lattanzio R; Spadaccini A; Fiorella S; Polimeni F; Polimeni N; Stoppino V; Stoppino G; Giorgetti GM; Aiello F; Danese S
Aliment Pharmacol Ther; 2013 Oct; 38(7):741-51. PubMed ID: 23957734
[TBL] [Abstract][Full Text] [Related]
19. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS.
Tack J; Schumacher K; Tonini G; Scartoni S; Capriati A; Maggi CA;
Gut; 2017 Aug; 66(8):1403-1413. PubMed ID: 27196574
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
